Drug intelligence / Profile preview

XB010 + pembrolizumab

Development stage: Unknown
Lead developer: Exelixis
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**XB010 + pembrolizumab** is a combination therapy being investigated for the treatment of locally advanced or metastatic solid tumors. XB010 is a monoclonal antibody developed by Exelixis, while pembrolizumab (Keytruda) is an immune checkpoint inhibitor targeting PD-1. The combination aims to enhance the immune response against cancer cells by combining XB010’s antitumor mechanisms with pembrolizumab’s ability to block the PD-1 pathway and activate T-cell mediated immune responses. This therapeutic approach may offer improved efficacy compared to pembrolizumab monotherapy in a range of solid tumors[1][2][3][6][8].

Other names: XB010 + pembrolizumab

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on XB010 + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XB010 + pembrolizumab.

Explore the full profile